EMTRIM

This brand name is authorized in Nigeria.

Active ingredients

The drug EMTRIM contains a combination of these active pharmaceutical ingredients (APIs):

1	Sulfamethoxazole UNII JE42381TNV - SULFAMETHOXAZOLE
	Sulfamethoxazole competitively inhibits the utilisation of para-aminobenzoic acid in the synthesis of dihydrofolate by the bacterial cell resulting in bacteriostasis.
	Read more about Sulfamethoxazole
2	Trimethoprim UNII AN164J8Y0X - TRIMETHOPRIM
	Trimethoprim is a dihydrofolate reductase inhibitor, inhibiting the conversion of bacterial dihydrofolic acid to tetrahydrofolic acid, required for the synthesis of some amino acids. Its effects are considerably greater on the cells of micro-organisms than on the mammalian cells.
	Read more about Trimethoprim

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
04-0267	Tablet	Emtrim Tablet TAB 400 mg; 80 mg 10 x 10's; 100 x 10's; 1 x 1000's	White uncoated tablets, with EMTRIM embossed on one side of the tablet	30/11/2023
04-1456	Suspension	Emtrim Suspension SUSP 200 mg/5 mL; 40mg/5 mL	Each 5 mL suspension contains: Sulfamethoxazole 200 mg, Trimethoprim 40 mg	28/09/2020
A4-3601	Tablet	Emtrim Forte Caplet TAB 800 mg; 160 mg 10 x 10's; 100 x 10's; 1 x 500's	White uncoated tablets, with EMTRIM embossed on one side of the tablet	27/03/2024
B4-3242	Dispersible tablet	Emtrim Dispersible Tablet TAB_ORALLY_DIS 100 mg; 20 mg 10 x 10's; 100 x 10's	Dispersible tablet. White uncoated tablets, with EMTRIM embossed on one side of the tablet	30/11/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01EE01	Sulfamethoxazole and trimethoprim	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01E Sulfonamides and trimethoprim → J01EE Combinations of sulfonamides and trimethoprim, incl. derivatives
Discover more medicines within J01EE01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	04-0267, 04-1456, A4-3601, B4-3242